Published in Thromb Haemost on September 01, 2005
Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis (2006) 0.94
Inherited platelet disorders: thrombocytopenias and thrombocytopathies. Blood Transfus (2009) 0.89
Novel Mutation in Bernard-Soulier Syndrome. Transfus Med Hemother (2010) 0.81
Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study. Orphanet J Rare Dis (2014) 0.78
A Brazilian case of Bernard-Soulier syndrome with two distinct founder mutations. Hum Genome Var (2017) 0.75
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95
Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron (2004) 2.94
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med (2002) 2.42
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med (2007) 2.37
Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust (2009) 2.21
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res (2007) 2.10
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood (2010) 1.75
Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. Arterioscler Thromb Vasc Biol (2010) 1.74
Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood (2010) 1.68
Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood (2009) 1.65
Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature (2002) 1.63
Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells results in reversible LIF-independent self-renewal. Stem Cells (2009) 1.63
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost (2005) 1.54
Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood (2006) 1.54
Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem (2002) 1.46
Snake venom L-amino acid oxidases. Toxicon (2002) 1.41
NF-M is an essential target for the myelin-directed "outside-in" signaling cascade that mediates radial axonal growth. J Cell Biol (2003) 1.41
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica (2008) 1.41
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost (2005) 1.40
Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood (2008) 1.37
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology (2006) 1.36
Platelets at work in primary hemostasis. Blood Rev (2011) 1.34
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem (2005) 1.34
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood (2004) 1.30
Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion (2007) 1.30
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell (2007) 1.26
Sox2 is essential for formation of trophectoderm in the preimplantation embryo. PLoS One (2010) 1.26
Essential alterations of heparan sulfate during the differentiation of embryonic stem cells to Sox1-enhanced green fluorescent protein-expressing neural progenitor cells. Stem Cells (2007) 1.23
Mesenchymal stem cells: isolation, characterisation and in vivo fluorescent dye tracking. Heart Lung Circ (2008) 1.20
Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc Natl Acad Sci U S A (2005) 1.19
Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. J Neurochem (2005) 1.16
Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood (2005) 1.15
Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open (2013) 1.14
A prospective study on the prevalence and risk factors for neonatal thrombocytopenia and platelet alloimmunization among 9332 unselected Brazilian newborns. Transfusion (2007) 1.13
Unwinding the von Willebrand factor strings puzzle. Blood (2012) 1.13
von Willebrand factor to the rescue. Blood (2009) 1.13
Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant (2004) 1.08
Abrogation of E-cadherin-mediated cellular aggregation allows proliferation of pluripotent mouse embryonic stem cells in shake flask bioreactors. PLoS One (2010) 1.06
European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol (2003) 1.05
Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol (2012) 1.03
Specific glycosaminoglycans modulate neural specification of mouse embryonic stem cells. Stem Cells (2011) 1.03
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol (2008) 1.02
Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J (2003) 1.01
An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Transfusion (2004) 1.01
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol (2007) 1.01
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood (2006) 0.99
Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost (2006) 0.98
Molecular evolution of the vertebrate blood coagulation network. Thromb Haemost (2003) 0.98
Antiplatelet drugs. Br J Haematol (2008) 0.98
Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol (2004) 0.97
Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. J Oncol (2010) 0.97
Spectrum of the mutations in Bernard-Soulier syndrome. Hum Mutat (2014) 0.97
Inherited traits affecting platelet function. Blood Rev (2008) 0.97
E-cadherin and, in its absence, N-cadherin promotes Nanog expression in mouse embryonic stem cells via STAT3 phosphorylation. Stem Cells (2012) 0.95
Activation of alphaIIbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets. Blood (2006) 0.95
High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem (2003) 0.95
Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. Blood (2004) 0.93
Haemodynamic changes during early bereavement: potential contribution to increased cardiovascular risk. Heart Lung Circ (2010) 0.93
Genome-wide occupancy links Hoxa2 to Wnt-β-catenin signaling in mouse embryonic development. Nucleic Acids Res (2012) 0.92
A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood (2005) 0.92
Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost (2013) 0.91
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood (2008) 0.91
Monoclonal antibody IAC-1 is specific for activated alpha2beta1 and binds to amino acids 199 to 201 of the integrin alpha2 I-domain. Blood (2004) 0.91
Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study. Thorax (2012) 0.90
Heterogeneity of HPA-3 alloantibodies: consequences for the diagnosis of alloimmune thrombocytopenic syndromes. Transfusion (2007) 0.90
Multicenter evaluation of a whole-blood filter that saves platelets. Transfusion (2004) 0.90
The crystal structure of the platelet activator aggretin reveals a novel (alphabeta)2 dimeric structure. Biochemistry (2008) 0.90
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for genotyping of human platelet-specific antigens. Transfusion (2008) 0.89
AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood (2011) 0.89
Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion (2004) 0.89
Two functional active conformations of the integrin {alpha}2{beta}1, depending on activation condition and cell type. J Biol Chem (2005) 0.89
Blood platelet biochemistry. Thromb Res (2011) 0.89
Von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord Drug Targets (2009) 0.89
A single-nucleotide polymorphism in the human ITGB3 gene is associated with the platelet-specific alloantigen Va (HPA-17bw) involved in fetal maternal alloimmune thrombocytopenia. Transfusion (2008) 0.88
Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer. Biochem J (2002) 0.88
Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients. Thromb Haemost (2007) 0.88
Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb Haemost (2008) 0.87
Alpha1-antitrypsin Pittsburgh in a family with bleeding tendency. Haematologica (2009) 0.87
Shear-stress-induced conformational changes of von Willebrand factor in a water-glycerol mixture observed with single molecule microscopy. J Phys Chem B (2014) 0.87
Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood (2012) 0.87
A naturally occurring LeuVal mutation in beta3-integrin impairs the HPA-1a epitope: the third allele of HPA-1. Transfusion (2006) 0.86
E-cadherin acts as a regulator of transcripts associated with a wide range of cellular processes in mouse embryonic stem cells. PLoS One (2011) 0.86
CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS One (2010) 0.86
Alloantibodies against low-frequency human platelet antigens do not account for a significant proportion of cases of fetomaternal alloimmune thrombocytopenia: evidence from 1054 cases. Transfusion (2009) 0.86
Effect of omega-3 fish oil on cardiovascular risk in diabetes. Diabetes Educ (2010) 0.86
The effect of initial treatment of periodontitis on systemic markers of inflammation and cardiovascular risk: a randomized controlled trial. Eur J Oral Sci (2010) 0.86